|Bid||19.00 x 1200|
|Ask||25.00 x 900|
|Day's Range||21.34 - 21.89|
|52 Week Range||18.24 - 27.38|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MOUNTAIN VIEW, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will report financial results for the second quarter of 2021 after market close on Thursday, August 12, 2021. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /4:30 p.m. Eastern Time. Investors interested in listening to the
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
NeuroPace (NASDAQ: NPCE), is growing the implantable device market for treating drug-resistant focal epilepsy and setting itself up to dominate it for years to come. With an offering that provides better outcomes than its competition, significant penetration into epilepsy centers across the U.S., and potential label expansions that could just about double its current addressable market, this company could offer significant upside to investors. NeuroPace makes a $50,000 implantable device, the RNS (Responsive Neurostimulation) System, that continuously monitors epilepsy patients' brain activity and responds to patient-specific seizure patterns.